After demonstrating that miR-504 could reverse ME signatures by directly targeting FZD7 in GBM, we comprehensively evaluated the potential of the combination of miR-504 and FZD7 as a novel biomarker of ME subtype GBM. The gene discussed is FZD7; the disease is glioblastoma.